Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Boston Scientific ( (BSX) ) just unveiled an announcement.
Boston Scientific Corporation has announced the resumption of its AVANT GUARD clinical trial, focusing on drug-naïve patients with persistent atrial fibrillation. This decision follows a thorough assessment and collaboration with the study’s data monitoring committee, signaling potential advancements in treatment options for this patient group.
Find detailed analytics on BSX stock on TipRanks’ Stock Analysis page.
